Consensus Immatics N.V.

Stocks

IMTX

NL0015285941

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-26 EDT			5-day change	1st Jan Change
7.150 ^USD	-2.19%		+1.42%	-31.90%

10-24	Immatics N.V. Presents Updated Clinical Trial Data from Ongoing Phase 1B Study with IMA402 PRAME Bispecific and Phase 1 Study with IMA203CD8 PRAME Cell Therapy	CI
10-23	Certain Restricted Share Units of Immatics N.V. are subject to a Lock-Up Agreement Ending on 24-OCT-2026.	CI

Evolution of the Average Target: Immatics N.V.

Evolution of the Target Price: Immatics N.V.

Changes in Analyst Recommendations: Immatics N.V.

bcc0637ba22a27dfd13172c6a.uFaBjzKhRZ-YFa_8M8WzQ2bdwfY2YsOoptAts6AKZLk.3jXQxFf2F8rHUNejcYDfLlKC9L9EN6vcy7xGnuc7FsrdPNf1dMx3puhg9g~d6239fcdde61d17b903808b56ede0ed0

Analysts' recommendations: Immatics N.V.

10-14	Stifel Initiates Immatics at Buy With $15 Price Target	MT
04-28	TD Cowen Initiates Immatics at Buy	MT
03-06	Deutsche Bank Lifts Price Target on Immatics to $18 From $17, Keeps Buy Rating	MT
01-06	Biotech Sector Poised for Growth Driven by Trial Data, Pharma Deals, BofA Says	MT
01-06	BofA Adjusts Price Target on Immatics to $17 From $14, Maintains Buy Rating	MT
11-19	Mizuho Raises Price Target on Immatics to $23 From $19, Keeps Outperform Rating	MT
25-09-18	Guggenheim Initiates Coverage on Immatics N.V With Buy Rating, $16 Price Target	MT
25-05-28	Deutsche Bank Initiates Coverage on Immatics With Buy Rating, $10 Price Target	MT
25-01-07	BofA Securities Adjusts Price Target on Immatics to $13 From $15, Maintains Buy Rating	MT
24-10-07	Piper Sandler Initiates Immatics With Overweight Rating, $19 Price Target	MT
24-05-15	Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating	MT
23-11-02	Cantor Fitzgerald Initiates Coverage on Immatics with Overweight Rating	MT
23-08-18	Mizuho Ups Price Target on Immatics to $14 From $12, Maintains Buy Rating	MT
23-03-31	Mizuho Initiates Immatics at Buy With $12 Price Target	MT
23-03-23	Chardan Adjusts Price Target on Immatics to $25 From $28, Keeps Buy Rating	MT
22-08-10	Chardan Research Adjusts Price Target on Immatics to $28 From $30, Reiterates Buy Rating	MT
22-06-03	SVB Securities Adjusts Immatics NV's Price Target to $26 from $25, Keeps Outperform Rating	MT
22-03-24	SVB Leerink Adjusts Immatics' Price Target to $25 from $32, Keeps Outperform Rating	MT
21-12-14	SVB Leerink Adjusts Immatics PT to $32 From $28, Maintains Outperform Rating	MT
21-07-15	Immatics N : SVB Leerink Adjusts Immatics NV's Price Target to $27 from $26, Keeps Outperform Rating	MT
21-03-18	Immatics N : Chardan Adjusts Immatics' Price Target to $30 From $28, Reiterates Buy Rating	MT
21-03-17	Immatics N : SVB Leerink Adjusts Immatics NV Price Target to $26 From $17, Maintains Outperform Rating	MT
20-11-20	Immatics N : BofA Securities Starts Immatics at Buy With $13 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IMMATICS N.V.					+132.17%
	WUXI APPTEC CO., LTD.					+32.59%
	ARGENX SE					+28.07%
	LONZA GROUP AG					+10.26%
	IQVIA HOLDINGS INC.					+8.34%
	BEONE MEDICINES AG					+15.58%
	REVOLUTION MEDICINES, INC.					+38.17%
	CELLTRION, INC.					+38.53%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.23%
	GENMAB A/S					+4.99%
	Average					+33.99%
	Weighted average by Cap.					+23.60%